Recombinant activated factor VII for a warfarinised Jehovah's Witness with an acute subdural haematoma

Journal of Clinical Neuroscience

Volumn 15, Issue 10, 2008, Pages 1164-1166

  Goldberg, Rimma ^a   Drummond, Katharine J ^a,b  

^a ROYAL MELBOURNE HOSPITAL   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

Author keywords

Acute subdural haematoma; Anticoagulation; Jehovah's Witness; Recombinant activated factor VIII; Surgery; Warfarin

Indexed keywords

BLOOD CLOTTING FACTOR 7; HEMOGLOBIN; RECOMBINANT BLOOD CLOTTING FACTOR 7A; WARFARIN;

AGED; ARTICLE; BLEEDING; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; CRANIECTOMY; FEMALE; HEMOGLOBIN BLOOD LEVEL; HUMAN; INTERNATIONAL NORMALIZED RATIO; JEHOVAH'S WITNESS; PRIORITY JOURNAL; SUBDURAL HEMATOMA;

AGED; ANTICOAGULANTS; ATRIAL FIBRILLATION; COAGULANTS; FACTOR VII; FEMALE; HEMATOMA, SUBDURAL, ACUTE; HUMANS; JEHOVAH'S WITNESSES; RECOMBINANT PROTEINS; TREATMENT OUTCOME; WARFARIN;

EID: 50249179708     PISSN: 09675868     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jocn.2007.05.030     Document Type: Article

References (11)

1. Kessler C. Haemorrhagic complications of thrombocytopenia and oral anticoagulation: is there a role for recombinant activated factor VII?. Intensive Care Med 28 Suppl.2 (2002) S228-S234
2. Majumdar G., and Savidge G.F. Recombinant factor VIIa for intracranial haemorrhage in a Jehovah's Witness with severe haemophilia A and factor VIII inhibitors. Blood Coagul Fibrinolysis 4 (1993) 1031-1033
3. Davis S.M., and Kaye A.H. Therapy for intracerebral hemorrhage. J Clin Neurosci 12 (2005) 219-220
4. Mayer S.A., Brun N.C., Begtrup K., et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 352 (2005) 777-785
5. Karadimov D., Binev K., Nachkov Y., et al. Use of activated recombinant Factor VII (NovoSeven) during neurosurgery. J Neurosurg Anesthesiol 15 (2003) 330-332
6. Pickard J.D., Kirkpatrick P.J., Melsen T., et al. Potential role of NovoSeven in the prevention of rebleeding following aneurysmal subarachnoid haemorrhage. Blood Coagul Fibrinolysis 11 Suppl.1 (2000) S117-S120
7. Brody D.L., Aiyagari V., Shackleford A.M., et al. Use of recombinant factor VIIa in patients with warfarin-associated intracranial hemorrhage. Neurocrit Care 2 (2005) 263-267
8. Lin J., Hanigan W.C., Tarantino M., et al. The use of recombinant activated factor VII to reverse warfarin-induced anticoagulation in patients with hemorrhages in the central nervous system: preliminary findings. J Neurosurg 98 (2003) 737-740
9. Erhardtsen E., Nony P., Dechavanne M., et al. The effect of recombinant factor VIIa (NovoSeven) in healthy volunteers receiving acenocoumarol to an International Normalized Ratio above 2.0. Blood Coagul Fibrinolysis 9 (1998) 741-748
10. Fewel M.E., and Park P. The emerging role of recombinant-activated factor VII in neurocritical care. Neurocrit Care 1 (2004) 19-29
11. Watch Tower Bible and Tract Society of Pennsylvania. Bloodless Medicine and Surgery, Some of the Methods. http://www.watchtower.org/e/20000108/diagram_01.htm; accessed April 2007.